The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
Elesta's ECHOLASER X4 has cleared FDA 510(k) review under product code GEX, with a determination of substantial equivalence for general and plastic surgery applications. The clearance broadens the device's labeling beyond dermatology-only use, opening it to surgical centers and hospital-based practices.
The ECHOLASER platform uses a hybrid laser technology and has been used in Europe for years. The 510(k) pathway—rather than a more rigorous PMA—suggests Elesta positioned it against existing general surgical lasers rather than claiming novel mechanism. This matters for practices: the device can now be marketed to plastic surgeons and general surgeons in the US, not just dermatologists and aestheticians.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
General surgery clearance opens the device to surgical centers and hospital-based practices.
For medspa owners, the competitive implication is modest. The clearance doesn't displace InMode, Cutera, or Sciton in the aesthetic laser space, but it signals another entrant willing to pursue the US market through predicate-based clearance.
What is the ECHOLASER X4 and what did it just get FDA clearance for?
The ECHOLASER X4 is Elesta's hybrid laser platform that recently cleared FDA 510(k) review under product code GEX for general and plastic surgery applications. Previously cleared only for dermatology, the new clearance expands its use to surgical centers and hospital-based practices in the US.
What's the difference between 510(k) and PMA clearance for surgical lasers?
510(k) is a faster, predicate-based pathway that requires demonstrating substantial equivalence to an existing device, while PMA is a more rigorous review for novel mechanisms. Elesta pursued 510(k) by positioning the ECHOLASER X4 against existing general surgical lasers rather than claiming a new technology.
Does the ECHOLASER X4 clearance threaten existing medspa laser companies?
The clearance poses minimal competitive threat to established aesthetic laser brands like InMode, Cutera, and Sciton in the medspa space. It primarily signals another vendor entering the US market through predicate-based clearance, with its main addressable market being surgical centers and plastic surgeons rather than aesthetics-focused practices.
How long has the ECHOLASER X4 been used before US FDA clearance?
The ECHOLASER platform has been used in Europe for years before gaining US FDA clearance, demonstrating a track record outside the American market before entering it through the 510(k) pathway.
Can medspa owners now purchase and use the ECHOLASER X4?
Yes, the FDA clearance now allows the ECHOLASER X4 to be marketed to dermatologists, aestheticians, plastic surgeons, and general surgeons in the US. However, medspa adoption will depend on pricing, clinical outcomes, and competitive positioning against established aesthetic laser platforms.
Business information, not medical or legal advice. Verify product status at FDA.gov.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.
